Aquestive Clears a Key FDA Hurdle for Its Needle-Free Allergy Drug — But Can a $630 Million Company Really Take On EpiPen?

Shares of Aquestive Therapeutics jumped +9.1% to $4.30 Monday morning after the company reported that its under-the-tongue epinephrine film — a postage-stamp-sized strip designed to replace needle injectors for severe allergic reactions — passed both usability and drug-absorption studies that the FDA had demanded. The data clears the last known scientific obstacle before the company refiles its application for approval, now targeted for this quarter. With Q2 earnings due tomorrow, the timing is no accident.

• The FDA's January Rejection Wasn't About the Drug — It Was About the Packaging. The agency's January 30 rejection letter flagged deficiencies in "human factors validation, including potential challenges associated with pouch opening and film placement," along with a request for one additional drug-absorption study. Crucially, clinical comparisons to auto-injectors like EpiPen and Auvi-Q "were not questioned," and no manufacturing issues were identified. Today's positive results mean self-administration drug-absorption results were comparable to clinician-administered results, and revised packaging addressed the FDA's concerns. That is a narrow, fixable problem — not a fundamental flaw in the science.

• The Q3 Resubmission Is Now a Credible Timeline, Not Just Guidance. The company says it is on track to resubmit the application in Q3 2026. Management has repeated this target since February, but today's data converts a promise into evidence. Under standard FDA review timelines, a resubmission could yield a decision by early 2027. In parallel, the company continues advancing regulatory submissions in Canada, the UK, and the EU.

• The Cash Runway Question Looms Over Everything. Aquestive holds $110.7 million in cash against $43.6 million in debt , but it burned $44.3 million in free cash flow over the past twelve months.

Share count has grown 23.3% in a year , diluting existing investors. At roughly $630 million in market value, the stock prices in significant approval odds — but a second rejection would be devastating to a company with roughly two years of cash left.

• Needle-Free Competition Is Already on the Market. ARS Pharmaceuticals' nasal epinephrine spray received FDA approval in May 2025 , giving it a head start among the roughly 40 million Americans at chronic risk for anaphylaxis.

Aquestive believes its film can be the "first and only non-invasive, orally delivered epinephrine product," but first now means first oral — a narrower claim in an increasingly crowded field.